New molecular targets against cervical cancer

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• Martin-HirschPLWoodNJCervical cancerClin Evid (Online)20112011081821791123
   PubMedGoogle Scholar
• PlanteMEvolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapyInt J Gynecol Cancer201323698298923792600
   PubMed Web of Science ®Google Scholar
• EifelPJWinterKMorrisMPelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01J Clin Oncol200422587288014990643
   PubMed Web of Science ®Google Scholar
• PetersWA3rdLiuPYBarrettRJ2ndConcurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervixJ Clin Oncol20001881606161310764420
   PubMed Web of Science ®Google Scholar
• Gynecologic Oncology GroupCisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer Available from: http://clinicaltrials.gov/show/NCT01414608. NLM identifier: NCT01414608Accessed June 15, 2014
   Google Scholar
• University College, LondonInduction chemotherapy plus chemoradiation as first line treatment for locally advanced cervical cancer (INTERLACE) Available from: http://clinicaltrials.gov/show/NCT01566240. NLM identifier: NCT01566240Accessed June 15, 2014
   Google Scholar
• ScatchardKForrestJLFlubacherMCornesPWilliamsCChemotherapy for metastatic and recurrent cervical cancer [review]Cochrane Database Syst Rev201210CD00646923076924
   PubMed Web of Science ®Google Scholar
• TewariKSSillMWLongHJ3rdImproved survival with bevacizumab in advanced cervical cancerN Engl J Med2014370873474324552320
   PubMed Web of Science ®Google Scholar
• Chemoradiotherapy for Cervical Cancer Meta-Analysis CollaborationReducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trialsJ Clin Oncol200826355802581219001332
   PubMed Web of Science ®Google Scholar
• PetrelliFDe StefaniARaspagliesiFLorussoDBarniSRadiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysisGynecol Oncol2014134116617124793000
   PubMed Web of Science ®Google Scholar
• MonkBJSillMWMcMeekinDSPhase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol200927284649465519720909
   PubMed Web of Science ®Google Scholar
• CellaDHuangHQMonkBJHealth-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group studyGynecol Oncol2010119353153720837359
   PubMed Web of Science ®Google Scholar
• COSMIC (Catalouge of somatic mutations in cancer) [database on the Internet]Hinxton, UKWellcome Trust Sanger Institute Available from: http://cancer.sanger.ac.uk/cell_lines/browse/tissue?ss=NS&sn=cervixAccessed October 29, 2014
   Google Scholar
• OjesinaAILichtensteinLFreemanSSLandscape of genomic alterations in cervical carcinomasNature2014506748837137524390348
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWLeeYCMannelRA Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyInt J Gynecol Cancer200919592993319574787
   PubMed Web of Science ®Google Scholar
• Nogueira-RodriguesAdo CarmoCCViegasCPhase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancerClin Cancer Res200814196324632918829516
   PubMed Web of Science ®Google Scholar
• Nogueira-RodriguesAMoralezGGrazziotinRPhase II trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancerCancer201412081187119324615735
   PubMed Web of Science ®Google Scholar
• GoncalvesAFabbroMLhommeCA Phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancerGynecol Oncol20081081424617980406
   PubMed Web of Science ®Google Scholar
• SharmaDNRathGKJulkaPKGandhiAKJagadesanPKumarSRole of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from AsiaInt J Gynecol Cancer201323470570923466569
   PubMed Web of Science ®Google Scholar
• HertleinLLenhardMKirschenhoferACetuximab monotherapy in advanced cervical cancer: a retrospective study with five patientsArch Gynecol Obstet2011283110911320180130
   PubMed Web of Science ®Google Scholar
• SantinADSillMWMcMeekinDSPhase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyGynecol Oncol2011122349550021684583
   PubMed Web of Science ®Google Scholar
• FarleyJSillMWBirrerMPhase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group studyGynecol Oncol2011121230330821329967
   PubMed Web of Science ®Google Scholar
• KurtzJEHardy-BessardACDeslandresMCetuximab, topotecan, and cisplatin for the treatment of advanced cervical cancer: a Phase II GINECO trialGynecol Oncol20091131162019232434
   PubMed Web of Science ®Google Scholar
• MooreKNSillMWMillerDSA Phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: a Gynecologic Oncology Group studyGynecol Oncol2012127345646122960004
   PubMed Web of Science ®Google Scholar
• von Knebel DoeberitzMGissmannLzur HaussenHGrowth-regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expressionCancer Res19905012373037361692767
   PubMed Web of Science ®Google Scholar
• CandelariaMArias-BonfillDChavez-BlancoALack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alphaInt J Gynecol Cancer20091991632163719955950
   PubMed Web of Science ®Google Scholar
• MackayHJTinkerAWinquistEA Phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184Gynecol Oncol2010116216316719740535
   PubMed Web of Science ®Google Scholar
• TinkerAVEllardSWelchSPhase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced, or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)Gynecol Oncol2013130226927423672928
   PubMed Web of Science ®Google Scholar
• TemkinSMYamadaSDFlemingGFA Phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignanciesGynecol Oncol2010117347347620347480
   PubMed Web of Science ®Google Scholar
• GaffneyDKWinterKDickerAPEfficacy and patterns of failure for locally advanced cancer of the cervix treated with Celebrex (celecoxib) and chemoradiotherapy in RTOG 0128Int J Radiat Oncol Biol Phys200769111111717482376
   PubMed Web of Science ®Google Scholar
• TanSde VriesEGvan der ZeeAGde JongSAnticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancerCurr Cancer Drug Targets201212217018422165971
   PubMed Web of Science ®Google Scholar
• GhoshUBhattacharyyaNPInduction of apoptosis by the inhibitors of poly(ADP-ribose) polymerase in HeLa cellsMol Cell Biochem20093201–2152318695944
   PubMed Web of Science ®Google Scholar
• ReinboltREHaysJLThe role of PARP inhibitors in the treatment of gynecologic malignanciesFront Oncol2013323724098868
   PubMedGoogle Scholar
• Duenas-GonzalezALizanoMCandelariaMCetinaLArceCCerveraEEpigenetics of cervical cancer. An overview and therapeutic perspectivesMol Cancer200543816248899
   PubMed Web of Science ®Google Scholar
• ManiEMedinaLAIsaac-OliveKDuenas-GonzalezARadiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproateEur J Gynaecol Oncol201435214014224772915
   PubMed Web of Science ®Google Scholar
• CandelariaMCetinaLPerez-CardenasEEpigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancerEur J Gynaecol Oncol201031438639120882878
   PubMed Web of Science ®Google Scholar
• CoronelJCetinaLPachecoIA double-blind, placebo-controlled, randomized Phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary resultsMed Oncol201128Suppl 1S540S54620931299
   PubMed Web of Science ®Google Scholar
• StaflAMatinnglyRFAngiogenesis of cervical neoplasiaAm J Obstet Gynecol197512168458521119492
   PubMed Web of Science ®Google Scholar
• GuidiAJAbu-JawdehGBerseBVascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasiaJ Natl Cancer Inst19958716123712457563170
   PubMedGoogle Scholar
• LeeJSKimHSParkJTLeeMCParkCSExpression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 statusAnal Quant Cytol Histol200325630331114714296
   PubMed Web of Science ®Google Scholar
• LoncasterJACooperRALogueJPDavidsonSEHunterRDWestCMVascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervixBr J Cancer200083562062510944602
   PubMed Web of Science ®Google Scholar
• ChengWFChenCALeeCNWeiLHHseihFJHseihCYVascular endothelial growth factor and prognosis of cervical carcinomaObstet Gynecol2000965 Pt 172172611042307
   PubMed Web of Science ®Google Scholar
• FujiwakiRHataKIidaKMaedeYMiyazakiKVascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosisAnticancer Res2000202B1317132210810442
   PubMed Web of Science ®Google Scholar
• WrightJDVivianoDPowellMABevacizumab combination therapy in heavily pretreated, recurrent cervical cancerGynecol Oncol2006103248949316647106
   PubMed Web of Science ®Google Scholar
• TanSJJuanJHFuPTYuMHLaiHCChemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancerEur J Gynaecol Oncol201031335035321077488
   PubMed Web of Science ®Google Scholar
• MonkBJSillMWBurgerRAGrayHJBuekersTERomanLDPhase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecology Oncology Group studyJ Clin Oncol20092771069107419139430
   PubMed Web of Science ®Google Scholar
• ZighelboimIWrightJDGaoFMulticenter Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancerGynecol Oncol20131301646823591400
   PubMed Web of Science ®Google Scholar
• SchefterTWinterKKwonJSRTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinomaInt J Radiat Oncol Biol Phys201488110110524331655
   PubMed Web of Science ®Google Scholar
• Duenas-GonzalezAZarbaJJPatelFPhase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervixJ Clin Oncol201129131678168521444871
   PubMed Web of Science ®Google Scholar
• MonkBJMas LopezLZarbaJJPhase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancerJ Clin Oncol201028223562356920606083
   PubMed Web of Science ®Google Scholar
• MonkBJPanditeLNSurvival data from a Phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancerJ Clin Oncol20112936484522084371
   PubMed Web of Science ®Google Scholar
• WedgeSRKendrewJHennequinLFAZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerCancer Res200565104389440015899831
   PubMed Web of Science ®Google Scholar
• Diaz-PadillaISiuLLBrivanib alanitate for cancerExpert Opin Investig Drugs2011204577586
   PubMed Web of Science ®Google Scholar
• Wise-DraperTMWellsSIPapillomavirus E6 and E7 proteins and their cellular targetsFront Biosci2008131003101717981607
   PubMed Web of Science ®Google Scholar
• MungerKScheffnerMHuibregtseJMHowleyPMInteractions of HPV E6 and E7 oncoproteins with tumour suppressor gene productsCancer Surv1992121972171322242
   PubMedGoogle Scholar
• Narisawa-SaitoMKiyonoTBasic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteinsCancer Sci200798101505151117645777
   PubMed Web of Science ®Google Scholar
• YugawaTKiyonoTMolecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteinsRev Med Virol20091929711319156753
   PubMed Web of Science ®Google Scholar
• GoodwinECDiMaioDRepression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathwaysProc Natl Acad Sci U S A20009723125131251811070078
   PubMed Web of Science ®Google Scholar
• MacvilleMSchrockEPadilla-NashHComprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotypingCancer Res19995911411509892199
   PubMed Web of Science ®Google Scholar
• SimaNWangWKongDInterference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53Apoptosis200813227328118060502
   PubMed Web of Science ®Google Scholar
• JiangMMilnerJSelective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interferenceOncogene200221396041604812203116
   PubMed Web of Science ®Google Scholar
• SimaNWangSWangWAntisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cellsGynecol Oncol2007106229930417586029
   PubMed Web of Science ®Google Scholar
• BousarghinLTouzeAGaudGInhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAsMol Cancer Ther20098235736519174559
   PubMed Web of Science ®Google Scholar
• GuWPutralLHengstKInhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenesCancer Gene Ther200613111023103216810314
   PubMed Web of Science ®Google Scholar
• PutralLNBywaterMJGuWRNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatinMol Pharmacol20056851311131916120770
   PubMed Web of Science ®Google Scholar
• MoonMSLeeCJUmSJParkJSYangJMHwangESEffect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cellsGynecol Oncol200180216817511161855
   PubMed Web of Science ®Google Scholar
• LeaJSSunagaNSatoMSilencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical of cervical cancer cellsReprod Sci2007141202817636212
   PubMed Web of Science ®Google Scholar
• ZhouYZhangCLiangWDevelopment of RNAi technology for targeted therapy – a track of siRNA based agents to RNAi therapeuticsJ Control Release Epub562014
   Web of Science ®Google Scholar
• ZhaoCYSzekelyLBaoWSelivanovaGRescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradationCancer Res20107083372338120395210
   PubMed Web of Science ®Google Scholar
• MungalaRKausarHMunjalCGuptaRCWithaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in humancervical cancer cellsCarcinogenesis201132111697170521859835
   PubMed Web of Science ®Google Scholar
• AllenKLTschantzDRAwadKSLynchWPDeLuciaALA plant lignan, 3′-O–methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cellsMol Carcinog200746756457517393435
   PubMed Web of Science ®Google Scholar
• BeerheideWSimMMTanYJBernardHUTingAEInactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfidesBioorg Med Chem20008112549256011092540
   PubMed Web of Science ®Google Scholar
• BalejaJDCherryJJLiuZIdentification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteinsAntiviral Res2006721495916690141
   PubMed Web of Science ®Google Scholar
• ChoYChoCJoungOLeeKParkSYoonDDevelopment of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP bindingAntiviral Res200047319920610974372
   PubMed Web of Science ®Google Scholar
• AbdulkarimBSabriSDeutschEAntiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancersOncogene200221152334234611948417
   PubMed Web of Science ®Google Scholar
• SirianniNWangJFerrisRLAntiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivityOral Oncol200541442342815792615
   PubMed Web of Science ®Google Scholar
• YangYZhaoXChenWEffects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude miceOncol Res20101811–1251952720939427
   PubMed Web of Science ®Google Scholar
• SnoeckRAndreiGDe ClercqECidofovir in the treatment of HPV-associated lesionsVerh K Acad Geneeskd Belg20016329312011436421
   PubMedGoogle Scholar
• Van PachterbekeCBucellaDRozenbergSTopical treatment of CIN 2+ by cidofovir: results of a Phase II, double-blind, prospective, placebo-controlled studyGynecol Oncol20091151697419647859
   PubMed Web of Science ®Google Scholar